Q1 FY25 saw 11% revenue growth and 20% higher PBT (ex-JV), with strong formulation segment expansion and stable API margins. The injectable facility is set for Q4 FY25 launch, and long-term growth guidance remains unchanged.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.